Pharmaceutical Compositions Comprising Modified Beta-Cyclodextrins
Sulfobutyl ether-beta-cyclodextrin enhances the solubility of compounds of formula (I), addressing low water solubility issues and enabling effective cancer treatment as a single agent.
Patent Information
- Application Number
- JP2024535753
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-22
- Filing Date
- 2022-12-14
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2042-12-14
AI Technical Summary
Compounds of formula (I), which are dual TTK/PLK1 inhibitors, exhibit low water solubility, limiting their exposure and effectiveness as a single agent in treating cancer.
The use of sulfobutyl ether-beta-cyclodextrin (SBE-beta-CD) as a solubilizing agent to enhance the solubility of compounds of formula (I) in pharmaceutical compositions, allowing for intravenous administration without exceeding the maximum acceptable daily intake (ADI).
SBE-beta-CD effectively solubilizes compounds of formula (I), enabling their administration as a single agent in mouse tumor models, demonstrating therapeutic potential for treating neoplastic diseases like cancer.
Smart Images

Figure 2024544083000001 
Figure 2024544083000002 
Figure 2024544083000003
Abstract
Description
[Technical field]
[0001] The present invention relates to pharmaceutical compositions comprising the active pharmaceutical compounds described below and modified beta-cyclodextrin excipients, and methods of using the pharmaceutical compositions for the treatment of neoplastic diseases, particularly cancer. [Background technology]
[0002] WO 2015 / 155042 describes a recently discovered class of inhibitors of threonine tyrosine kinase (TTK) for use in the treatment of cancer.
[0003] Cyclodextrins are cyclic oligosaccharides containing six (alpha-cyclodextrin), seven (beta-cyclodextrin) or eight (gamma-cyclodextrin) glucose units linked via alpha-1,4-glycosidic bonds. Derivatized versions of cyclodextrins are used as pharmaceutical excipients. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] International Publication No. 2015 / 155042 Summary of the Invention
[0005] Means for solving the problem Summary of the Invention In a first aspect, the present invention provides a compound of formula (I) [ka] or a pharma- ceutically acceptable salt thereof and a modified beta-cyclodextrin The present invention provides a pharmaceutical composition comprising:
[0006] As a dual TTK / Polo-like kinase 1 (PLK1) inhibitor, the compound of formula (I) represents a first-in-class of an emerging class of next-generation mitotic therapeutics and, to the best of our knowledge, is the only TTK inhibitor that induces regression (and cure) when administered as a single agent in mouse tumor models. However, the compound of formula (I) has poor aqueous solubility, which may limit its exposure in humans.
[0007] For the Phase I study, we aimed to develop a formulation capable of delivering up to 500 mg of compound of formula (I) as an intravenous infusion over 30-60 minutes, taking into account the poor solubility of compound of formula (I) and the maximum acceptable daily intakes (ADIs) of the excipients used to improve solubilization of the active pharmaceutical ingredient (API). Surprisingly, sulfobutylether-beta-cyclodextrin was found to provide acceptable solubilization of compound of formula (I) without exceeding its maximum ADI.
[0008] In a further aspect, the present invention provides a method of treating a neoplastic disease, such as cancer, in a patient in need thereof, comprising administering to said patient a pharmaceutical composition of the present invention, e.g., in a therapeutically effective amount.
[0009] In a further aspect, the present invention provides a pharmaceutical composition of the invention for use in treating a neoplastic disease, such as cancer, in a patient.
[0010] In a further aspect, the present invention provides the use of a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of a neoplastic disease, such as cancer, in a patient.
[0011] Further aspects and embodiments of the invention are described in more detail below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] General definition Certain terms used herein are described below: Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0013] The term "pharmaceutical composition" is defined herein to refer to a liquid formulation containing at least one therapeutic agent, together with one or more pharma- ceutically acceptable excipients, that is administered to a patient to prevent or treat a particular disease or condition affecting the patient.
[0014] The term "pharmacologically acceptable" as used herein refers to those items, such as compounds, materials, compositions and / or dosage forms, that are suitable, within the scope of sound medical judgment, for contact with the tissues of warm-blooded animals, e.g., mammals or humans, without excessive toxicity or other complications commensurate with a reasonable benefit / risk ratio.
[0015] The term "treatment", as used herein in relation to treating a neoplastic disease in a patient, generally refers to treatments and therapies in which some desired therapeutic effect is achieved, such as inhibition of the progression of the neoplastic disease, including slowing the rate of progression, stopping the rate of progression, alleviating the symptoms of the neoplastic disease, ameliorating the neoplastic disease, and curing the neoplastic disease. For example, treatment can be the attenuation of one or several symptoms of a disorder or the complete eradication of a disorder such as cancer. Within the meaning of this disclosure, the term "treat" also means stopping the disease, delaying its onset (i.e., the period before the clinical manifestation of the disease), and / or reducing the risk of developing or worsening the disease.
[0016] The term "pharmacologically effective amount," "therapeutically effective amount," or "clinically effective amount" is an amount sufficient to result in an observable or clinically significant improvement over baseline clinically observable signs and symptoms of the disorder being treated with the pharmaceutical composition.
[0017] The term "patient" refers to a human presenting himself / herself for therapeutic treatment.
[0018] The term "about" refers to a variation of up to 10% of the associated figure. In some embodiments, the term "about" refers to a variation of up to 5% of the associated figure.
[0019] Where ranges are given, the endpoints of the range are included within the range.
[0020] Compounds of formula (I) References to the compound of formula (I) refer to the free base and pharma- ceutically acceptable salts of the compound of formula (I) above. In some embodiments, references to the compound of formula (I) refer to the free base of the compound of formula (I). In other embodiments, references to the compound of formula (I) refer to the pharma- ceutically acceptable salts of the compound of formula (I).
[0021] The pharmaceutically acceptable salt of the compound of formula (I) can be an acid addition salt.Salt is formed, for example, with organic or inorganic acid from the compound of formula (I).Pharmaceutically acceptable salt is within the scope of the common knowledge of those skilled in the art.Pharmaceutically acceptable salt can contain two or more molecules or ions of corresponding acid.
[0022] The compounds of formula (I) and pharma- ceutically acceptable salts thereof may be synthesised as described in WO 2015 / 155042, which is incorporated herein by reference, in particular pages 17-19, and as described in Example 17 on page 49 of WO 2015 / 155042 (including references to Examples 17-9, Intermediate H and Example 1, which are also incorporated herein by reference).
[0023] In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is about 1 mg / mL to about 3.5 mg / mL based on the compound of formula (I) as a free base. In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is about 1 mg / mL to about 3 mg / mL based on the compound of formula (I) as a free base. In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is about 1.5 mg / mL to about 2.5 mg / mL based on the compound of formula (I) as a free base.
[0024] In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is up to about 3.5 mg / mL based on the compound of formula (I) as a free base. In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is up to about 3 mg / mL based on the compound of formula (I) as a free base. In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is up to about 2.5 mg / mL based on the compound of formula (I) as a free base.
[0025] In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is at least about 1 mg / mL based on the compound of formula (I) as a free base. In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition of the present invention is at least about 1.5 mg / mL based on the compound of formula (I) as a free base.
[0026] In some embodiments, the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in a pharmaceutical composition of the invention is about 2 mg / mL based on the compound of formula (I) as a free base.
[0027] Generally, a higher solubilized concentration of the compound of formula (I) in the pharmaceutical composition of the present invention can be achieved at a lower pH.
[0028] The phrase "based on the compound of formula (I) as the free base" means that, when a pharma- ceutically acceptable salt of the compound of formula (I) is used, the amount in mg / mL of the pharma- ceutically acceptable salt of the compound of formula (I) is the molar equivalent of the stated amount in mg / mL of the free base of the compound of formula (I).
[0029] Modified beta-cyclodextrin Cyclodextrins interact with hydrophobic drug molecules to form inclusion complexes. Beta-cyclodextrin has a relatively low water solubility, and modification of beta-cyclodextrin by replacement of any of the hydrogen bond-forming hydroxyl groups, even by lipophilic substituents, results in a dramatic improvement in the water solubility of the derivative. Hydrophobic, hydrophilic, polymeric, ionized, non-ionized and many other derivatives of cyclodextrin have been developed, with the substituents including neutral, anionic and / or cationic functional groups.
[0030] Modified cyclodextrins, such as alkylated cyclodextrins, include, for example, sulfoalkyl ether cyclodextrins, alkyl ether cyclodextrins (e.g., methyl, ethyl and propyl ether cyclodextrins), hydroxyalkyl cyclodextrins, thioalkyl ether cyclodextrins, carboxylated cyclodextrins (e.g., succinyl-beta-cyclodextrin, etc.), sulfated cyclodextrins, etc. Alkylated cyclodextrins having two or more types of functional groups, such as sulfoalkyl ether-alkyl ether-cyclodextrins (see, for example, WO 2005 / 042584 and U.S. Patent Application Publication No. 2009 / 0012042), are also known.
[0031] Specific examples of modified beta-cyclodextrin derivatives used as excipients in pharmaceutical products are the sulfobutyl ether derivatives of beta-cyclodextrin (SBE-beta-CD), the hydroxypropyl derivatives of beta-cyclodextrin (HP-beta-CD), and randomly methylated beta-cyclodextrin (RM-beta-CD).
[0032] The structure of the modified beta-cyclodextrin is shown below (Formula II), where each R independently represents hydrogen or an aliphatic substituent, and at least one R is not hydrogen. [ka]
[0033] Note that in SBE-beta-CD, R is -(CH2)4-SO3Na, in HP-beta-CD, R is -CH2-CHOH-CH3, and in RM-beta-CD, R is -CH3 (see, e.g., Cyclodextrins Used as Excipients, EMA / CHMP / 333892 / 2013), where in each case R is a mixture of a given substituent and hydrogen. For a further review of the use of cyclodextrins in pharmaceuticals, particularly parenteral formulations, see Loftsson, Journal of Pharmaceutical Sciences 2021, 110:654-664.
[0034] SBE-beta-CD has the CAS number 182410-00-0 and is sold, for example, under the trade names Captisol™ (Ligand) and Dexolve™ (Cyclolab). It is listed in both the European Pharmacopoeia and the United States Pharmacopoeia. Captisol™ has a molecular weight of 2163 g / mol based on an average degree of substitution of 6.5 (www.captisol.com). According to US Pat. No. 9,493,582, the degree of substitution in Captisol™ is 6-7.1. Dexolve™ also has an average degree of substitution of 6.5 (www.cyclolab.hu). SBE-beta-CD can be prepared, for example, as described in U.S. Patent Application Publication No. 2009 / 011037, U.S. Patent Application Publication No. 2009 / 270348, U.S. Patent Application Publication No. 2015 / 045311, U.S. Patent Application Publication No. 2015 / 284479, and U.S. Patent Application Publication No. 2016 / 009826, all of which are incorporated by reference.
[0035] In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has a degree of substitution of about 2 to about 9. In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has a degree of substitution of about 4.5 to about 7.5. In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has a degree of substitution of about 6 to about 7.5. In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has a degree of substitution of about 6.5.
[0036] In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has an average degree of substitution of about 2 to about 9. In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has an average degree of substitution of about 4.5 to about 7.5. In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has an average degree of substitution of about 6 to about 7.5. In some embodiments, the modified beta-cyclodextrin (e.g., SBE-beta-CD) has an average degree of substitution of about 6.5. In some embodiments, the modified beta-cyclodextrin is SBE-beta-CD having CAS number 182410-00-0.
[0037] The degree of substitution is a measure of the number of substituents attached to the modified beta-cyclodextrin molecule in terms of moles of substituents per mole of modified beta-cyclodextrin. The average degree of substitution is a measure of the total number of substituents present per modified beta-cyclodextrin molecule in terms of the distribution of the modified beta-cyclodextrin within the modified beta-cyclodextrin product used in the pharmaceutical composition of the invention.
[0038] The amount of modified beta-cyclodextrin (e.g., SBE-beta-CD) used in the pharmaceutical composition of the present invention should be sufficient to dissolve the compound of formula (I) or a pharma- ceutically acceptable salt thereof. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the present invention is about 10 mg / mL to about 400 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the present invention is about 10 mg / mL to about 200 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the present invention is about 10 mg / mL to about 100 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the present invention is about 20 mg / mL to about 60 mg / mL. In some embodiments, the concentration of the modified beta-cyclodextrin (eg, SBE-beta-CD) in the pharmaceutical composition of the invention is from about 30 mg / mL to about 50 mg / mL.
[0039] In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the invention is up to about 400 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the invention is up to about 200 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the invention is up to about 100 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the invention is up to about 60 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in the pharmaceutical composition of the invention is up to about 50 mg / mL.
[0040] In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in a pharmaceutical composition of the invention is at least about 10 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in a pharmaceutical composition of the invention is at least about 20 mg / mL. In some embodiments, the concentration of modified beta-cyclodextrin (e.g., SBE-beta-CD) in a pharmaceutical composition of the invention is at least about 30 mg / mL.
[0041] In some embodiments, the concentration of the modified beta-cyclodextrin (eg, SBE-beta-CD) in the pharmaceutical composition of the invention is about 40 mg / mL.
[0042] pH, additives, composition As discussed above, the pH of the composition affects the solubility of the compound of formula (I) in SBE-beta-CD, with solubility increasing at lower pH.
[0043] In some embodiments, the pH of the pharmaceutical composition of the present invention is about 3.5 to about 9, keeping in mind that higher pH values correspond to lower solubility of the compound of formula (I). In some embodiments, the pH of the pharmaceutical composition of the present invention is about 3.5 to about 7. In some embodiments, the pH of the pharmaceutical composition of the present invention is about 4 to about 6.5. In some embodiments, the pH of the pharmaceutical composition of the present invention is about 4.5 to about 6.5. In some embodiments, the pH of the pharmaceutical composition of the present invention is 4.5 to 6.5. In some embodiments, the pH of the pharmaceutical composition of the present invention is about 4.5 to about 5.5.
[0044] In some embodiments, the pH of the pharmaceutical composition of the invention is at least about 3.5. In some embodiments, the pH of the pharmaceutical composition of the invention is at least about 4. In some embodiments, the pH of the pharmaceutical composition of the invention is at least about 4.5. In some embodiments, the pH of the pharmaceutical composition of the invention is at least 4.5.
[0045] In some embodiments, the pH of the pharmaceutical composition of the present invention is up to about 9. In some embodiments, the pH of the pharmaceutical composition of the present invention is up to about 7. In some embodiments, the pH of the pharmaceutical composition of the present invention is up to about 6.5. In some embodiments, the pH of the pharmaceutical composition of the present invention is up to 6.5. In some embodiments, the pH of the pharmaceutical composition of the present invention is up to about 5.5.
[0046] In some embodiments, the pH of a pharmaceutical composition of the present invention is about 5.5.
[0047] The pH of the pharmaceutical composition of the present invention can be maintained by suitable buffering agents.Examples include citrate, acetate, gluconate, lactate and aspartate.Those skilled in the art will recognize many other suitable buffering agents that can be used with the pharmaceutical composition of the present invention to control pH.
[0048] The buffer may be used at a concentration determined by a person skilled in the art to be appropriate, such as about 5 mM to about 100 mM, for example, about 10 mM to about 100 mM, for example, about 20 mM to about 50 mM, for example, up to about 100 mM, for example, up to about 50 mM, for example, at least about 10 mM, for example, at least about 20 mM, for example, about 30 mM.
[0049] The pharmaceutical composition may include an osmotic agent such as a salt, e.g., sodium chloride, in addition to the buffer. The salt, e.g., sodium chloride, may be used at a concentration deemed appropriate by the skilled artisan. In some embodiments, the salt may be omitted. When salt is present, a concentration such as about 0.5 mg / mL to about 10 mg / mL may be used, e.g., about 0.5 mg / mL to about 8 mg / mL, e.g., about 1 mg / mL to about 8 mg / mL, e.g., about 2 mg / mL to about 6 mg / mL, e.g., up to about 10 mg / mL, e.g., up to about 8 mg / mL, e.g., up to about 6 mg / mL, e.g., at least about 0.5 mg / mL, e.g., at least about 1 mg / mL, e.g., at least about 2 mg / mL, e.g., at least about 3 mg / mL, e.g., about 3 mg / mL.
[0050] Other additives may be used in the pharmaceutical compositions of the invention, such as antioxidants including butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides or other carbohydrates including glucose, mannose or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or non-ionic surfactants such as Tween™ (e.g., Tween™ 80), Pluronics™, or polyethylene glycol (PEG); as well as the cosolvents, hydrophilic polymers and surfactants described in the Examples below.
[0051] *In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5), and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0052] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 1 mg / mL to about 3 mg / mL based on the compound of formula (I) as a free base, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5), and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0053] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 1.5 mg / mL to about 2.5 mg / mL based on the compound of formula (I) as a free base, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5), and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0054] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 200 mg / mL, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0055] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 100 mg / mL, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0056] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 30 mg / mL to about 50 mg / mL, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0057] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 1 mg / mL to about 3 mg / mL based on the compound of formula (I) as a free base, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 200 mg / mL, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0058] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 1 mg / mL to about 3 mg / mL based on the compound of formula (I) as the free base, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 100 mg / mL, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0059] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 1.5 mg / mL to about 2.5 mg / mL based on the compound of formula (I) as a free base, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 30 mg / mL to about 50 mg / mL, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0060] In some embodiments, the pharmaceutical composition comprises a compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 2 mg / mL based on the compound of formula (I) as a free base, and SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 40 mg / mL, and the pH of the pharmaceutical composition is 4.5 to 6.5 (e.g., about 5.5).
[0061] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as a free base, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5), one or more buffering agents, optionally a salt, and optionally water, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0062] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base in a concentration of about 1 mg / mL to about 3 mg / mL, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5), one or more buffering agents, optionally a salt, and optionally water, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0063] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base in a concentration of about 1.5 mg / mL to about 2.5 mg, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5), one or more buffering agents, optionally a salt, and optionally water, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0064] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 200 mg / mL, one or more buffering agents, optionally a salt, and optionally water, wherein the pH of the pharmaceutical composition is about 4 to about 6.5.
[0065] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 100 mg / mL, one or more buffering agents, optionally a salt, and optionally water, wherein the pH of the pharmaceutical composition is about 4 to about 6.5.
[0066] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 30 mg / mL to about 50 mg / mL, one or more buffering agents, optionally a salt, and optionally water, wherein the pH of the pharmaceutical composition is about 4 to about 6.5.
[0067] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base in a concentration of about 1 mg / mL to about 3 mg / mL, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 200 mg / mL, one or more buffering agents, optionally a salt, and optionally water, wherein the pH of the pharmaceutical composition is about 4 to about 6.5.
[0068] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base in a concentration of about 1 mg / mL to about 3 mg / mL, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 10 mg / mL to about 100 mg / mL, one or more buffering agents, optionally a salt, and optionally water, wherein the pH of the pharmaceutical composition is about 4 to about 6.5.
[0069] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base in a concentration of about 1.5 mg / mL to about 2.5 mg / mL, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 30 mg / mL to about 50 mg / mL, one or more buffering agents, optionally a salt, and optionally water, and the pH of the pharmaceutical composition is about 4 to about 6.5.
[0070] In some embodiments, the pharmaceutical composition consists essentially of a compound of formula (I) as the free base in a concentration of about 2 mg / mL, SBE-beta-CD (e.g., having an average degree of substitution of about 6 to about 7.5) in a concentration of about 40 mg / mL, one or more buffering agents, optionally a salt, and optionally water, and the pH of the pharmaceutical composition is 4.5 to 6.5 (e.g., about 5.5).
[0071] In some embodiments, the pharmaceutical composition is one in which the components and amounts of each component per mL of pharmaceutical composition are as follows: [Table 1]
[0072] In some embodiments, the pharmaceutical composition is one in which the components and amounts of each component per mL of pharmaceutical composition are as follows: [Table 2]
[0073] In some embodiments, the pharmaceutical composition is one in which the components and amounts of each component per mL of pharmaceutical composition are as follows: [Table 3]
[0074] In some embodiments, the pharmaceutical composition is one in which the components and amounts of each component per mL of pharmaceutical composition are as follows: [Table 4]
[0075] An exemplary pharmaceutical composition is one in which the components and amounts of each component per mL of pharmaceutical composition are as follows: [Table 5]
[0076] Manufacturing method The compound of formula (I) and its pharma- ceutically acceptable salts can be prepared as described above. The modified beta-cyclodextrin can be prepared as described above or obtained from a commercial source. The pharmaceutical composition of the present invention can be prepared by charging an initial volume of water (WFI) to a container, adding a buffer, adjusting the pH to a desired level, for example using hydrochloric acid, and then adding the compound of formula (I) or its pharma- ceutically acceptable salt, for example as a powder, and mixing until dissolved. The process can be continued by adding the modified beta-cyclodextrin and mixing until dissolved. After dissolution of the compound of formula (I) or its pharma- ceutically acceptable salt and the modified beta-cyclodextrin, the pH can be adjusted to correspond to the desired pH range and the solution can be made up to volume with water. The pharmaceutical composition can be sterilized by filtering using a 0.2 μm filter. Finally, the pharmaceutical composition can be aliquoted into vials and sealed. Those skilled in the art will recognize that alternative manufacturing methods are also possible.
[0077] The pharmaceutical compositions of the invention may be administered intravenously to a patient either undiluted or after dilution, for example with physiological saline.
[0078] Uses of the Pharmaceutical Compositions of the Invention The pharmaceutical composition of the present invention can be used to treat neoplastic diseases such as cancer, for example, by intravenous administration. The pharmaceutical composition of the present invention can be used to treat cancer at any clinical stage or pathological grade (e.g., tumor stage I, tumor stage II, tumor stage III, tumor stage IV) or treatment setting (e.g., preventive, adjuvant, neoadjuvant, therapeutic, including palliative treatment). The pharmaceutical composition of the present invention can be for use in delaying, delaying or stopping cancer progression or cancer growth, or increasing overall survival time or cancer progression-free survival time or time to cancer progression, or improving or maintaining the quality of life or functional status of a patient (e.g., a patient). The pharmaceutical composition of the present invention can also be used in post-treatment recovery from cancer. The pharmaceutical composition of the present invention can be used to treat metastatic cancer.
[0079] For example, the pharmaceutical compositions of the present invention may be used to (i) reduce the number of cancer cells; (ii) reduce tumor volume; (iii) increase tumor regression rate; (iv) reduce or delay cancer cell invasion into peripheral organs; (v) reduce or delay tumor metastasis; (vi) reduce or inhibit tumor growth; (vii) prevent or delay the onset and / or recurrence of cancer and / or extend disease-free or tumor-free survival; (viii) increase overall survival; (ix) reduce the frequency of treatments; and / or (x) alleviate one or more symptoms associated with cancer.
[0080] As mentioned above, the pharmaceutical composition of the present invention can be used to treat neoplastic disease.The examples of neoplastic disease include but are not limited to epithelial neoplasm, squamous cell neoplasm, basal cell neoplasm, transitional cell papilloma and carcinoma, adenoma and adenocarcinoma, adnexal and skin adnexal neoplasm, mucoepidermoid neoplasm, cystic neoplasm, mucinous and serous neoplasm, ductal, lobular and intramedullary neoplasm, acinar cell neoplasm, complex epithelial neoplasm, special glandular neoplasm, paraganglioma and breast tumor, nevus and melanoma, soft tissue tumor and sarcoma, fibroma neoplasm, myxoma neoplasm, lipoma neoplasm, fibroma neoplasm, complex mixed and stromal neoplasm. , fibroepithelial neoplasms, synovial neoplasms, mesothelioma neoplasms, germ cell neoplasms, trophoblastic neoplasms, mesogiomas, vascular tumors, lymphatic tumors, osseous and chondromatous neoplasms, giant cell tumors, various bone tumors, odontogenic tumors, gliomas, neuroepithelioma neoplasms, meningiomas, nerve sheath tumors, granular cell tumors and alveolar soft part sarcomas, Hodgkin's and non-Hodgkin's lymphomas, other lymphoreticular neoplasms, plasma cell neoplasms, mast cell tumors, immunoproliferative disorders, leukemias, various myeloproliferative disorders, lymphoproliferative disorders and myelodysplastic syndromes.
[0081] In some embodiments, neoplastic disease is cancer.Examples of cancers of affected body organs and parts include, but are not limited to, brain, breast (including triple negative breast cancer and luminal B breast cancer), cervix, ovary, colon, rectum (including colorectum, i.e. colorectal cancer), lung (including small cell lung cancer, non-small cell lung cancer, large cell lung cancer and mesothelioma), endocrine system, bone, adrenal gland, thymus, liver, stomach, intestine (including gastric cancer), pancreas, bone marrow, hematological malignancies (e.g., lymphoma, leukemia, myeloma or lymphatic malignancies), bile duct, bladder, urinary tract, kidney, skin, thyroid, head and neck, prostate and testis.
[0082] In some embodiments, the neoplastic disease is a cancer selected from breast cancer (including triple-negative breast cancer and luminal B breast cancer), gastric cancer, colorectal cancer, liver cancer (including hepatocellular carcinoma), endometrial cancer, ovarian cancer, esophageal cancer, lung cancer (including non-small cell lung cancer), Kaposi's sarcoma, cervical cancer, pancreatic cancer, melanoma, prostate cancer, bladder cancer, and leukemia, e.g., acute myeloid leukemia (AML) (including mixed karyotype AML).
[0083] In some embodiments, the neoplastic disease is breast cancer.
[0084] In some embodiments, the neoplastic disease is triple-negative breast cancer.
[0085] In some embodiments, the neoplastic disease is luminal B breast cancer.
[0086] In some embodiments, the neoplastic disease is gastric cancer.
[0087] In some embodiments, the neoplastic disease is colorectal cancer.
[0088] In some embodiments, the neoplastic disease is hepatocellular carcinoma.
[0089] In some embodiments, the neoplastic disease is endometrial cancer.
[0090] In some embodiments, the neoplastic disease is acute myeloid leukemia (AML), including complex karyotype AML.
[0091] In some embodiments, the neoplastic disease is lung cancer (eg, small cell lung cancer, non-small cell lung cancer).
[0092] In some embodiments, the neoplastic disease is cervical cancer (eg, metastatic or recurrent cervical cancer).
[0093] In some embodiments, the neoplastic disease is head and neck cancer (eg, recurrent or metastatic squamous cell carcinoma of the head and neck).
[0094] In some embodiments, the neoplastic disease is Wilms' tumor.
[0095] In some embodiments, the neoplastic disease is a brain tumor (eg, a glioma, such as a progressive glioma or a recurrent glioma, a medulloblastoma, such as a recurrent medulloblastoma).
[0096] In some embodiments, the neoplastic disease is neuroblastoma.
[0097] In some embodiments, the neoplastic disease is testicular cancer (eg, metastatic non-seminomatous germ cell tumors).
[0098] In some embodiments, the neoplastic disease is bladder cancer (eg, advanced bladder cancer, including those with abnormal renal function).
[0099] In some embodiments, the neoplastic disease is retinoblastoma (eg, recurrent or progressive retinoblastoma).
[0100] The cancer may be a primary tumor and / or a metastasis. The cancer may originate from a solid or liquid (e.g., hematological or intraperitoneal) tumor. In some embodiments, the neoplastic disease (e.g., cancer) to be treated is a tumor, e.g., a solid tumor.
[0101] All aspects and embodiments of the invention described herein may be combined in any possible combination.
[0102] In order to more fully describe and disclose the present invention and the state of the art to which it pertains, several publications are cited herein. Each of these references is herein incorporated by reference in its entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.
[0103] Certain embodiments of the present invention are described in the following examples which serve to illustrate the present invention in more detail and should not be construed as limiting the invention in any way.
[0104] Working Example The compound of formula (I) as a free base compound has a very strong lipophilic behavior (Log P4.13). The presence of three main basic functional groups with calculated pKa of 8.9, 3.8, and 0.5 (MarvinSketch™ 18.24.0, ChemAxon Ltd.) makes it soluble in water at pH<1.8, but practically insoluble at pH≧4.5, with a solubility of ≦0.02 mg / mL. Considering these characteristics and based on the pH requirement of intravenous (IV) solutions, which is generally set at 4.0 or higher, solubility studies were performed to identify solubilizers that can substantially increase the aqueous solubility of the compound of formula (I).
[0105] method Solubility measurements were performed as follows: Prepare two vials for solubility testing at 0 hours (vial 1) and 24 hours (vial 2). Prepare vial contents starting with 2.5 mg of compound of formula (I). Add the primary excipient, followed by any additional excipients, then add buffered water to a total volume of 500 μL. Mix all components on a vortex mixer, for example for 5 minutes. Once everything is dissolved, add another 2.5 mg of compound of formula (I) and vortex again for about 5 minutes. Repeat this until a saturated solution (suspension) is obtained.
[0106] The solubility in vial 1 is measured immediately as described below. The ingredients in vial 2 are stirred together in a vial using a magnetic stirrer for 24 hours, then vortexed for, e.g., 5 minutes, before measuring the solubility.
[0107] To measure solubility, take 400 μl of the suspension and place it in a centrifuge over a 0.2 μm filter. Centrifugation is performed at 14,000 rpm for 10 minutes and repeated for another 10 minutes if necessary. Remove the filter from the vial and take 100 μl and dilute with 400 μl of high performance liquid chromatography (HPLC) diluent (see below) or 900 μl of HPLC diluent if 5 mg or more of the compound of formula (I) is used. Measure the pH of the solution. Take another 100 μl of the vial solution and dilute with 400 μl of HPLC diluent or 900 μl of HPLC diluent if 5 mg or more of the compound of formula (I) is used. Assay of the solution vs. the control stock solution is measured by HPLC and the solubility is calculated as described below. The HPLC diluent solution is 0.1% trifluoroacetic acid (TFA) in acetonitrile (ACN) and water (1:1 v / v).
[0108] Calibrate the pH meter used daily with standard buffer solutions (pH 2.00, 4.01, 7.00, and 9.00) and determine the slope and offset values. The specified pass criteria for slope are 90-105% and offset are -30 mV to 30 mV.
[0109] All solubility tests are performed at room temperature.
[0110] The HPLC method for assessing solubility is performed as follows. [Table 6] [Table 7]
[0111] The solubility of the compounds of formula (I) is calculated according to the following formula:
number
[0112] *Formulations for stability evaluation are prepared as follows: A 500 mL batch of each formulation (target pH 4.0 and pH 5.5) is prepared according to the recipe in Table 2 below. The vials used were 50 mL 20 mm crown, Type I, Vial (Gerresheimer), part number 80018303030. The stoppers used were 20 mm S10-F451 Stopper 4432 / 50 Gray, (Flurotec™ On Plug Only) B2-40 Coating Westar RS part number 19700021.
[0113] Each formulation is filtered through a 0.22 μm nylon syringe filter. Vials are filled with 10 mL of formulation, stoppered, sealed, and placed at 40° C. / 75% relative humidity (RH) or 60° C. (no humidity control) for up to 14 days. Each vial is placed upside down so that maximum stopper contact with the solution can be achieved during stable conditions. At each time point, vials from both conditions and formulations are removed and analyzed for assay and impurities. [Table 8]
[0114] Assay and impurities measured using the same HPLC method used to assess solubility.
[0115] result Effect of a single solubilizer A variety of potential solubilizing agents were tested for their ability to solubilize the compound of formula (I), as shown in Table 3. [Table 9-1] [Table 9-2]
[0116] High solubility of the compound of formula (I) at solubilizer concentrations suitable for intravenous use was observed with sulfobutyl ether beta-cyclodextrin (SBE-beta-CD). Low solubility of the compound of formula (I) was observed with other solubilizers tested at concentrations suitable for intravenous use, including hydroxypropyl beta-cyclodextrin. The concentration of PEG 400 and propylene glycol that results in higher solubility of the compound of formula (I) is 500 mg / mL, which is too high for intravenous use.
[0117] Effect of pH on solubility of SBE-beta-CD The effect of pH on the solubility of compounds of formula (I) with SBE-beta-CD was investigated, and the results are shown in Table 4. [Table 10]
[0118] The pH of the solution affects the solubility, with lower solubility of the compound of formula (I) observed at higher pH, and especially high solubility observed between pH 4 and pH 5.5. Effect of additional excipients on solubility
[0119] The effect of adding additional excipients on the solubility of compound of formula (I) with SBE-beta-CD was investigated and the results are shown in Table 5. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4]
[0120] It was observed that PEG 400, glycerol, propylene glycol and PEG 4000 do not increase the solubility of the compound of formula (I) with SBE-beta-CD. Solubilization with ethanol and PEG 300 is similar to PEG 400 (note that higher concentrations of SBE-beta-CD were used in these studies). Kollidon™ 12 PF, Kolliphor™ P188, soy lecithin have very little effect on the solubility with SBE-beta-CD. The addition of Tween™ 80 improves the solubility slightly. The addition of sodium carboxymethyl-cellulose reduces the solubility and the solution becomes viscous at 24 hours. These results also show that saline has very little effect on the solubility. Effect of buffer on solubility
[0121] The effect of different buffers on the solubility of compound of formula (I) with SBE-beta-CD was investigated and the results are shown in Table 6. [Table 12]
[0122] The solubility of the compound of formula (I) in the buffers tested (citrate, acetate, gluconate, lactate and aspartate buffers) was observed to be approximately the same. Effect of pH on stability
[0123] The effect of pH on the stability of the compound of formula (I) in formulations with SBE-beta-CD was examined, and the results are shown in Table 7. [Table 13]
[0124] The results show that the stability of formulations containing the compound of formula (I) and SBE-beta-CD is similar at pH 4.0 and pH 5.5 under 40° C. / 75% RH stress conditions, however, at 60° C. stress conditions, the pH 5.5 formulation had fewer impurities and less assay loss compared to the pH 4.0 formulation.
Claims
1. Compounds of formula (I) 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof and a pharmaceutical composition comprising a modified beta-cyclodextrin.
2. 2. The pharmaceutical composition of claim 1, wherein the modified beta-cyclodextrin is sulfobutyl ether beta-cyclodextrin (SBE-beta-CD).
3. 3. The pharmaceutical composition of claim 2, wherein the SBE-beta-CD has a degree of substitution of about 6 to about 7.
5.
4. 3. The pharmaceutical composition of claim 2, wherein the SBE-beta-CD has an average degree of substitution of about 6 to about 7.
5.
5. 3. The pharmaceutical composition of claim 2, wherein the SBE-beta-CD has an average degree of substitution of about 6.
5.
6. 6. The pharmaceutical composition of any one of claims 2 to 5, wherein the concentration of SBE-beta-CD in the pharmaceutical composition is up to about 400 mg / mL.
7. 6. The pharmaceutical composition of any one of claims 2 to 5, wherein the concentration of SBE-beta-CD in the pharmaceutical composition is from about 10 mg / mL to about 100 mg / mL.
8. 6. The pharmaceutical composition of any one of claims 2 to 5, wherein the concentration of SBE-beta-CD in the pharmaceutical composition is from about 30 mg / mL to about 50 mg / mL.
9. 9. The pharmaceutical composition of claim 1, wherein the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof in the pharmaceutical composition is up to about 3.5 mg / mL based on the compound of formula (I) as a free base.
10. 9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the concentration of said compound of formula (I) or a pharma- ceutically acceptable salt thereof is from about 1.5 mg / mL to about 2.5 mg / mL based on said compound of formula (I) as a free base.
11. 9. The pharmaceutical composition of any one of claims 1 to 8, wherein the concentration of the compound of formula (I) or a pharma- ceutically acceptable salt thereof is about 2 mg / mL based on the compound of formula (I) as a free base.
12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pH of the pharmaceutical composition is from about 3.5 to about 7.
13. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pH of the pharmaceutical composition is from about 4 to about 6.
5.
14. The pharmaceutical composition according to any one of claims 1 to 11, wherein the pH of the pharmaceutical composition is from 4.5 to 6.
5.
15. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a salt as an osmotic agent.
16. 16. The pharmaceutical composition of claim 15, wherein the salt is sodium chloride.
17. 17. The pharmaceutical composition of claim 15 or claim 16, wherein the salt concentration in the pharmaceutical composition is up to about 10 mg / mL.
18. The pharmaceutical composition according to claim 15 or 16, wherein the salt concentration in the pharmaceutical composition is from about 0.5 mg / mL to about 8 mg / mL.
19. 17. The pharmaceutical composition of claim 15 or 16, wherein the salt concentration in the pharmaceutical composition is about 3 mg / mL.
20. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises the compound of formula (I) or a pharma- ceutically acceptable salt thereof in a concentration of about 1 mg / mL to about 3 mg / mL based on the compound of formula (I) as a free base, and SBE-beta-CD having an average degree of substitution of about 6 to about 7.5 in a concentration of about 10 mg / mL to about 100 mg / mL, and wherein the pH of the pharmaceutical composition is about 4 to about 6.
5.
21. 2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists essentially of said compound of formula (I) as a free base, SBE-beta-CD having an average degree of substitution of about 6 to about 7.5, one or more buffering agents, optionally a salt, and optionally water, and wherein the pH of said pharmaceutical composition is from about 4 to about 6.
5.
22. 2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists essentially of said compound of formula (I) as the free base in a concentration of about 1 mg / mL to about 3 mg / mL, SBE-beta-CD having an average degree of substitution of about 6 to about 7.5 in a concentration of about 10 mg / mL to about 100 mg / mL, one or more buffering agents, optionally a salt, and optionally water, and wherein the pH of said pharmaceutical composition is about 4 to about 6.
5.
23. 2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists essentially of said compound of formula (I) as the free base in a concentration of about 1.5 mg / mL to about 2.5 mg / mL, SBE-beta-CD having an average degree of substitution of about 6 to about 7.5 in a concentration of about 30 mg / mL to about 50 mg / mL, one or more buffering agents, optionally a salt, and optionally water, and wherein the pH of said pharmaceutical composition is about 4 to about 6.
5.
24. 2. The pharmaceutical composition of claim 1, wherein the components and the amount of each component per mL of pharmaceutical composition are as follows: 【Table 1】
25. 21. The pharmaceutical composition of any one of claims 1 to 20, wherein the compound of formula (I) or a pharma- ceutically acceptable salt thereof is the compound of formula (I) as a free base.
26. 26. The pharmaceutical composition of any one of claims 1 to 25, wherein the term "about" refers to a variation of up to 5% of the associated figure.
27. 27. The pharmaceutical composition of any one of claims 1 to 26, wherein the pharmaceutical composition is suitable for intravenous administration.
28. 30. A pharmaceutical composition as defined in any one of claims 1 to 27 for use in treating a neoplastic disease in a patient.
29. 30. Use of a pharmaceutical composition as defined in any one of claims 1 to 28 in the manufacture of a medicament for the treatment of a neoplastic disease in a patient.
30. 28. A method of treating a neoplastic disease in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition as defined in any one of claims 1 to 27.
31. 29. The pharmaceutical composition for use according to claim 28, the use of the pharmaceutical composition according to claim 29, or the method according to claim 30, wherein the neoplastic disease is cancer.
32. 31. The pharmaceutical composition for use according to claim 28, the use of the pharmaceutical composition according to claim 29, or the method according to claim 30, wherein the neoplastic disease is a cancer selected from breast cancer, gastric cancer, colorectal cancer, liver cancer, endometrial cancer, ovarian cancer, esophageal cancer, lung cancer, Kaposi's sarcoma, cervical cancer, pancreatic cancer, melanoma, prostate cancer, bladder cancer and leukemia.
Citation Information
Patent Citations
Complex of ras farnesyltransferase inhibitor and sulfobutyl ether-7-β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin, and method for producing same
JP2002535253A
Antitumor composition containing compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazole-2-yl)-3-(2-morpholine-4-ylethyl)urea
JP2015525754A
Novel pharmaceutical composition
JP2016501874A
(5,6-dihydro)pyrimide[4,5-e]indolidine
JP2017510595A
(5,6-dihydro)pyrimido[4,5-e]indolizines
WO2015155042A1
